104 related articles for article (PubMed ID: 2465655)
1. Interferon production in myelo- and lymphoproliferative diseases. I. Spontaneous interferon production in acute and chronic leukaemias.
Szabó B; Tóth FD; Kiss J; Váczi L; Kiss A; Rák K
Acta Microbiol Hung; 1988; 35(3):295-300. PubMed ID: 2465655
[TBL] [Abstract][Full Text] [Related]
2. [Examination of interleukin levels and growth factor from blood platelets in leukemia].
Kiersnowska-Rogowska B; Rogowski F; Petelski T; Citko A; Jaroszewicz E; Bielawiec M
Pol Tyg Lek; 1996 May; 51(19-22):281-2, 288. PubMed ID: 9289710
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
7. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
Schmidt M; Hochhaus A; König-Merediz SA; Brendel C; Proba J; Hoppe GJ; Wittig B; Ehninger G; Hehlmann R; Neubauer A
J Clin Oncol; 2000 Oct; 18(19):3331-8. PubMed ID: 11013272
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
Kurzrock R; Kantarjian H; Wetzler M; Estrov Z; Estey E; Troutman-Worden K; Gutterman JU; Talpaz M
Exp Hematol; 1993 Jan; 21(1):80-5. PubMed ID: 8417962
[TBL] [Abstract][Full Text] [Related]
9. Clinical manifestations of chronic granulocytic leukemia.
Spiers AS
Semin Oncol; 1995 Aug; 22(4):380-95. PubMed ID: 7638635
[TBL] [Abstract][Full Text] [Related]
10. Platelet function in acute leukemias.
Naresh KN; Sivasankaran P; Veliath AJ
J Assoc Physicians India; 1993 Jun; 41(6):377-8. PubMed ID: 8005978
[TBL] [Abstract][Full Text] [Related]
11. Differentiation-inducing effect of recombinant human tumor necrosis factor alpha and gamma-interferon in vitro on blast cells from patients with acute myeloid leukemia and myeloid blast crisis of chronic myeloid leukemia.
Geissler K; Tricot G; Leemhuis T; Walker E; Broxmeyer HE
Cancer Res; 1989 Jun; 49(11):3057-62. PubMed ID: 2497971
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of lymphocytes and antibodies against autologous tumor cells in patients with myeloid leukaemias and preleukaemic disorders. III. Stage-dependence of oncovirus-specific immune response.
Szabó B; Tóth FD; Váczi L; Kiss J; Réthy A; Kiss A; Rák K
Acta Microbiol Hung; 1986; 33(2):103-10. PubMed ID: 3492851
[TBL] [Abstract][Full Text] [Related]
13. Lipid peroxidation in leukaemia.
Ghalaut VS; Ghalaut PS; Singh S
J Assoc Physicians India; 1999 Apr; 47(4):403-5. PubMed ID: 10778525
[TBL] [Abstract][Full Text] [Related]
14. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
15. Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
Aswald JM; Lipton JH; Messner HA
Cytokines Cell Mol Ther; 2002 Dec; 7(2):75-82. PubMed ID: 12607798
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
17. P53 protein expression in human leukemia and lymphoma cells.
Koníková E; Kusenda J
Neoplasma; 2001; 48(4):290-8. PubMed ID: 11712681
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
20. Antigenic phenotype of chronic granulocytic leukaemia progenitor cells in chronic phase and in blastic transformation characterized by means of monoclonal antibodies.
Robak T
Arch Immunol Ther Exp (Warsz); 1988; 36(4):471-85. PubMed ID: 3074744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
